Abstract: Pregnancy is a huge challenge for systemic lupus erythematosus（SLE） patients. Because hypercoagulable state can lead to various obstetric complications and adverse pregnancy outcomes. Therefore anticoagulant therapy is critical. The immune complex deposition and systemic inflammation cause placental structure injury, resulting in poor uteroplacental perfusion, and lead to imbalance of thromboxane A2（TXA2） and prostacycl, which is closely related to placental vascular thrombotic lesions. Aspirin by adjusting the balance of thromboxane and prostacyclin, inhibit platelet activity, and dilate blood vessels, which reducing the occurrence of adverse pregnancy outcomes and preventing obstetric complications. SLE and antiphospholipid syndrome（APS） pregnant women are recommended taking low-dose aspirin（40-160 mg/d） throughout pregnancy. Platelet aggregation test is an important indicator to monitor anti-platelet aggregation effect of the medicine. The safety of other anti-platelet aggregation medicine is still unknown. Heparin/low molecular weight heparin may be combined used according to the presence of the thrombosis and maternal miscarriage history.

Key words: Aspirin, Pregnant women, Lupus erythematosus, systemic, Antiphospholipid syndrome, Platelet aggregation